Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Immutep Ltd ( (AU:IMM) ).
Immutep Limited has reported significant progress in its oncology programs, particularly with the TACTI-004 Phase III trial for non-small cell lung cancer (NSCLC), which is expanding across numerous clinical sites globally. The company has achieved promising results in its INSIGHT-003 trial, showing high response and disease control rates in NSCLC patients. Additionally, Immutep’s combination therapy has demonstrated a strong median overall survival in head and neck cancer patients, potentially positioning the company for further regulatory discussions and market opportunities.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Limited is a clinical-stage biotechnology company focused on developing novel LAG-3 immunotherapies for cancer and autoimmune diseases. The company is actively involved in advancing its pipeline, particularly in oncology, with a strong emphasis on lung cancer and head and neck cancer treatments.
Average Trading Volume: 3,476,994
Technical Sentiment Signal: Sell
Current Market Cap: A$381.6M
Find detailed analytics on IMM stock on TipRanks’ Stock Analysis page.